1. FDA (Food and Drug Administration). Center for Drug Evaluation and Research (CDER), Bioavailability and Bioequivalence Studies for Orally Administered Drug Products. General Considerations, Rockville, MD. 2003.
2. EMA (European Medicines Agency). Evaluation of Medicines for Human Use, CPMP. Note for Guidance on the Investigation of Bioavailability and Bioequivalence, London. 2001.
3. EMA (European Medicines Agency). Committee for Medicinal Products for Human Use, CHMP. Guideline on the Investigation of Bioequivalence, London. 2010.
4. Blume H, Midha K. Bio-International ‘92, Conference on Bioavailability, Bioequivalence and Pharmacokinetic Studies. J Pharm Sci. 1993;82:1186–9.
5. Blume H, Elze M, Potthast H, et al. Practical strategies and design advantages in highly variable drug studies: multiple dose and replicate administration design. In: Blume H, Midha K, editors. Bio-international 2: Bioavailability, Bioequivalence and Pharmacokinetic studies. Stuttgart: Medpharm Scientific Publishers; 1995. p. 117–22.